Kornimate/medical-research-clean huggingface dataset:
effects of exercise training in patients with permanent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is a common arrhythmia. the proposed patholophysiological mechanisms of af include abnormal electrical conduction in atrium and sympathovagal imbalance with increased vagal tone. patients with af have poor exercise capacity that may contribute to decreased atrial effective refractory period, and decreased cardiac output and heart rate reserve, and may result in poor quality of life. poor endothelial function had been noted in patients with af, associated with increased risks of cerebrovascular and cardiovascular disease. exercise training has been noted to improve exercise capacity and quality of life in patients with af only in some studies. endothelial function can be improved by exercise training in patients with cardiovascular disease, but no report in patients with af. evidence of exercise training is still needed in patients with af. the purpose of this study is to investigate the effect of exercise training on 1. endothelial function 2. heart rate variability 3. exercise capacity 4. quality of life.

a randomized controlled study was implemented to examine :(1) the effect of interval aerobic exercise training combined with resistance training on endothelial function, heart rate variability (hrv), exercise capacity, and quality of life (qol); (2) the influential factors related to exercise capacity, and the relationship between exercise capacity and quality of life in patients with permanent atrial fibrillation (af).

Eligibility criteria:
inclusion criteria: * permanent atrial fibrillation≥ 1 year aged 40-76 years * recurrence af after ablation * under antiarrhythmia medication control exclusion criteria: * cad or myocardial infrarction history * nyha≥ iii-iv, or lvef≤45% * mitral or aortic valve regurgitation ≥ gr. ii * mitral valve or aortic valve stenosis * pacemaker * cardioversion by ablation * pulmonary artery hypertension * any surgery in previous 3 months * any neurological disorders * cancer * severe musculoskeletal disorder * hyperthyroidism * premenopausal women

Keywords: atrial fibrillation exercise training endothelial function autonomic nerve modulation exercise capacity quality of life
pharmacokinetics and safety of posaconazole tablet in participants at high risk for invasive fungal infections (mk-5592-065/p05615)

Conditions: Fungal Infections

Summary: the purpose of this study is to collect pharmacokinetic (pk) information related to how well posaconazole tablet is distributed in the body and to determine the safety of this new formulation. the study consists of a phase 1b study that includes participants with neutropenia undergoing chemotherapy for acute myelogenous leukemia (aml) or myelodysplasia (mds) and a phase 3 study that includes participants who are undergoing chemotherapy for aml or mds and participants who are recipients of allogeneic hematopoietic stem cell transplant (hsct).

participants with a blood disease or cancer that can affect their infection-fighting white blood cells and those who have undergone a hematopoietic stem cell transplant (hsct) and are receiving immunosuppressive therapy and have or are at risk of graft-vs-host disease (gvhd) are eligible for the study. these blood diseases and their treatments can weaken the immune system and may put individuals at high risk for a serious fungal infection of their internal organs or blood (invasive fungal infection). as these infections can be hard to detect early and can be life-threatening, many physicians believe that individuals diagnosed with these diseases should receive antifungal therapy to try to lower their risk of getting this type of infection. enrollment into this study will take place in several stages (parts). the determination of which part a participant will be in is based on which part is open at the site at the time of enrollment.

Eligibility criteria:
inclusion criteria: * body weight \>34 kg (75 lb) and of any race/ethnicity * able to swallow oral tablets whole * anticipated (likely to develop within 3-5 days) or documented neutropenia due to chemotherapy, chemotherapy for a new diagnosis of acute myelogenous leukemia (aml), or aml in first relapse; myelodysplastic syndromes (mds) in transformation to aml; allogeneic hematopoietic stem cell transplant (hsct) participants in the pre-engraftment period or in the post-engraftment period if they are receiving immunosuppressive therapy for graft versus host disease exclusion criteria: - female must not be pregnant, must not intend to become pregnant during the study, and must not be nursing * history of hypersensitivity to azoles * moderate or severe liver dysfunction defined as aspartate aminotransferase (ast) or alanine aminotransferase (alt) levels greater than three times the upper limit of normal (uln), and a total bilirubin level greater than two times the uln * electrocardiogram (ecg) with corrected qtc interval greater than 500 msec * posaconazole within 10 days before study enrollment * receipt of systemic antifungal therapy within 30 days of study enrollment for reasons other than antifungal prophylaxis * evidence of known or suspected invasive or systemic fungal infection at baseline * known or suspected history of gilbert's disease * creatinine clearance levels below 30 ml/min
a safety, tolerability, and pharmacokinetics study of a single intravenous injection of recombinant coagulation factor viii fc - von willebrand factor - xten fusion protein (rfviiifc-vwf-xten) (bivv001) in previously treated adults with severe hemophilia a (exten-a)

Conditions: Hemophilia A

Summary: the primary purpose was to assess the safety and tolerability of a single intravenous (iv) administration of bivv001 in adult previously treated patients (ptps) with severe hemophilia a.


Eligibility criteria:
inclusion criteria: * ability of the participant, or his legally authorized representative (e.g., parent or legal guardian) if applicable in accordance with local regulations, to understand the purpose and risks of the study and provide signed and dated informed consent/assent and authorization to use confidential health information in accordance with national and local participant privacy regulations. * severe hemophilia a, defined as less than (\ =) 1%, then a repeat endogenous fviii activity level was performed using the one stage clotting assay from the central laboratory. if the repeated result was \< 1 iu/dl (\<1%), then the participant met this inclusion requirement. * previous treatment for hemophilia a, defined as at least 150 documented prior exposure days to any recombinant and/or plasma-derived fviii and/or cryoprecipitate products at day 1. fresh frozen plasma treatment must not be considered in the count for documented exposure days. * platelet count \>=100,000 cells/ microliter (mcl) at screening (test performed by the central laboratory and reviewed prior to the day 1 advate dose). * a participant known to be human immunodeficiency virus (hiv) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to day 1 advate dose: cluster of differentiation 4 (cd4) lymphocyte count greater than (\>) 200 cells/millimeter (mm)\^3; viral load of \<400 copies/ml. exclusion criteria: medical history: * any concurrent clinically significant major disease that, in the opinion of the investigator, made the participant unsuitable for enrollment. * serious active bacterial or viral infection (other than chronic hepatitis or hiv) present within 30 days of screening. * other known coagulation disorder(s) in addition to hemophilia a. * history of hypersensitivity or anaphylaxis associated with any fviii product. * known or suspected allergy to mice, hamsters, or any ingredient in advate. * history of a positive inhibitor test or clinical signs of decreased response to fviii administrations. family history of inhibitors not excluded the participant. medications and procedures: - current enrollment or participation within 30 days prior to screening in any other investigational study. other: * inability to comply with study requirements as assessed by the investigator. * other unspecified reasons that, in the opinion of the investigator or sponsor, made the participant unsuitable for enrollment.
prevalence of cardiovascular risk factors in upper vestibular neuritis

Conditions: Vestibular Neuritis

Summary: vestibular neuritis is the second cause of vertigo, it constitutes 5 to 6% of the aetiologies of vertigo in an otoneurological consultation. infection or reactivation of a neurotropic virus of the herpes group (hsv-1) in the vestibular lymph node is thought to be the cause of the unilateral vestibular deficit. upper vestibular neuritis is more common than lower, or total involvement. goebel (2) explains this by an anatomical predisposition of the vestibular nerve canal to inflammation, unlike the singular nerve canal which is shorter and wider giving way to a certain degree of edema without consequence on its contents. however, the innervation territory of the superior vestibular nerve is superimposable on the territory supplied by the anterior vestibular artery. the anterior, lateral semicircular canals and the utricle are affected. current complementary vestibular and imaging examinations cannot differentiate between inflammatory or vascular involvement in upper vestibular neuritis. the increased presence of cardiovascular risk factors in patients with upper vestibular neuritis would be an argument in favor of ischemic involvement of the anterior vestibular artery.


Eligibility criteria:
nclusion criteria: * major subject (≥18 years old), * subject having presented an episode of upper vestibular neuritis recorded on the video head impulse test ulmer device at the hus between 01/01/2016 and 01/31/2020, * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * patient who expressed his opposition to participating in the study, * total vestibular neuritis, * impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.) * subject under safeguard of justice, * subject under guardianship or guardianship, * lack of video head impulse test data.

Keywords: vestibular neuritis anterior vestibular artery
comparison of the effectiveness of lllt and eswt in plantar fasciitis treatment

Conditions: Plantar Fascitis

Summary: the aim of this study is to compare the efficacy of extracorporeal shock wave therapy (eswt) and low-level laser therapy (lllt) in terms of pain, disability, activity limitation, gait speed, and cadence in patients with plantar fasciitis (pf).


Eligibility criteria:
inclusion criteria: * experience pain on the medial tuberosity or medial process of plantar fascia within the past one month * diagnosed with plantar fasciitis exclusion criteria: * arthritis in the foot or ankle * cardiac arrhythmia or pacemaker * previous foot or ankle surgery * cancer or tumor, acute trauma * bmi over 40 kg/m2 * corticosteroid injection in the last 6 months

Keywords: eswt lllt exercise
how much can the thoracic and lumbar skin slide?

Conditions: Movement of Thoracic and Lumbar Skin

Summary: the investigators want to determine how much the skin on the back can move left to right of the midline and also up and down, in subjects presenting for procedure or in healthy volunteers. the investigators will do measurements on the back using samples of individuals in all age groups. it is hypothesized that an explanation to late epidural failure could be related to excess back motion in individual subjects.


Eligibility criteria:
inclusion criteria: 1. children age 0-17 and adults 18 and older may participate 2. you agree to participate and sign the informed consent document exclusion criteria: 1. any type of back deformity 2. tumor on back 3. skin disease on the back 4. any condition that prevents skin measurements such as scleroderma
predicting and monitoring outcomes in autoimmune encephalitis

Conditions: Autoimmune Encephalitis

Summary: epilepsy is a disorder of the brain in which people have repeated seizures. autoimmune encephalitis (ae) is a rare cause of epilepsy. it is an inflammatory disease of the brain. this means that the body's own immune system attacks healthy brain tissue, just like it would if it were infected by a virus or a bacteria, by producing an army of proteins called 'antibodies' which go on to 'attack' healthy tissues. seizures in ae typically do not respond well to classic 'anti-seizure medications'. instead, medications which suppress the immune system are used. these can have significant side-effects and some patients will still continue to have seizures or experience a recurrence of ae-related epilepsy despite treatment. it is difficult to accurately predict who will experience these outcomes. this study aims to find ways of predicting and monitoring which people with ae are at greatest risk of these outcomes, so we can better direct them towards appropriate treatments. we will collect clinical information and samples of blood and cerebrospinal fluid (csf, fluid surrounding the brain and spinal cord) from people with ae and 'control' participants with other neurological illnesses. samples will be analysed for markers which may help predict or correlate with outcomes in ae and better understand this condition.


Eligibility criteria:
inclusion criteria: * ae participants over the age of 18 will be recruited if they meet the criteria for clinically probable or clinically definite autoimmune encephalitis as per graus and colleagues 2016. * neurological control participants undergoing lumbar puncture as part of clinical care for other, non-encephalitis disorders (e.g. for investigation of headache where meningitis or encephalitis is not detected, for investigation and treatment of idiopathic intracranial hypertension) in beaumont hospital will be recruited. exclusion criteria: ae participants * under 18 years of age * participants without ae or those with a definitive alternate diagnosis for presentation. other neurological control participants will be excluded if they have a current or historic diagnosis of ae.
safety and efficacy extension study of iron isomaltoside 1000 (monofer®) in subjects with inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Anaemia

Summary: since the duration of most studies with iv iron in ibd subjects have been only 4-12 weeks studies there is a need to follow-up on long term safety and efficacy of any maintenance iron therapy. this study represents subjects from the lead-in study (p-monofer-ibd-01) on iron isomaltoside 1000 (monofer®) to assess the long term safety of iron isomaltoside 1000 (monofer®) and its ability to maintain stable haemoglobin in ibd subjects with iron deficiency anaemia (ida).


Eligibility criteria:
inclusion criteria: 1. completed the lead-in study or discontinued from lead-in study due to intolerance to oral iron. 2. life expectancy beyond 18 months by investigator's judgement. 3. willingness to participate after informed consent. - exclusion criteria: 1. discontinuation from lead-in study (except for due to intolerance to oral therapy). 2. any major protocol deviation in lead-in study. 3. pregnancy and nursing \[to avoid pregnancy, women have to be postmenopausal, surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product (5 days): contraceptive pills, intrauterine devices (iud), contraceptive injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches\]. 4. any other medical condition that, in the opinion of investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. 5. patients with a harvey-bradshaw index \>8 or partial mayo score (excluding endoscopy sub-score) \>6 at end of study visit of lead-in study. -
a study to determine if two different versions of topotecan have the same potency in patients with advanced solid tumors

Conditions: Lung Cancer, Small Cell

Summary: the purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.


Eligibility criteria:
inclusion criteria: * subjects with advanced solid tumors. * at least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. * subjects must be free of post-treatment side effects. exclusion criteria: * women who are pregnant or lactating * subjects with uncontrolled emesis, regardless of etiology, active infection.

Keywords: any solid tumor
t-20 plus a selected anti-hiv treatment in hiv-infected children and adolescents

Conditions: HIV Infections

Summary: this study will evaluate t-20 in children.

children are stratified by age group (3 through 11 years and 12 through 16 years). samples for hiv-1 genotype and phenotype resistance testing are obtained at screening to aid in the selection of concomitant antiretrovirals. simultaneous to initiating t-20, all patients begin a "new" optimized antiretroviral regimen based on the patients' prior treatment history, historical resistance testing results, and the results of the testing performed at screening. patients are followed for safety and other assessments at weeks 1, 2, and 4, then monthly through week 24 and bimonthly through week 48. pharmacokinetic sampling at selected study visits are performed.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are 3 through 16 years of age and have the consent of parent or guardian. * have a viral load of at least 5000 copies/ml. * have taken at least 2 of the 3 licensed anti-hiv drug classes for at least 3 months. * have been on stable therapy for at least 4 weeks.

Keywords: anti-hiv agents pentafuside
bone microstructure by using hr-pqct after esophagectomy

Conditions: Osteoporosis; Sarcopenia; Esophageal Cancer

Summary: esophagectomy is most curative treatment to esophageal cancer. however, osteoporosis , which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after surgery. the aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (hr-pqct) in the long course after esophagectomy. at least 3 years should have elapsed since operation without recurrence of esophageal cancer.

the patients after esophagectomy loss appetite and decrease the weight. esophagectomy especially cause severe sarcopenia and metabolic change. osteoporosis, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after esophagectomy. the primary tools for assessing volumetric density and bone structure are quantitative computed tomography (qct) and more recently, high-resolution peripheral quantitative computed tomography (hr-pqct). however the validation of osteoporosis with hr-pqct in the long course after esophagectomy remain elusive. the aim of the present study was to evaluate osteoporosis by using hr-pqct in the long course after esophagectomy. at least 3 years should have elapsed since esophagectomy without any recurrence.

Eligibility criteria:
inclusion criteria: * at least 3 years have elapsed since esophagectomy due to esophageal cancer * provide signed informed consent exclusion criteria: * current use of the following osteoporosis agents; teriparatide, denosumab, and - - * bisphosphonate * present malignancy (except in situ carcinoma) * radiotherapy * any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy * other diseases which affect bone metabolism any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures received \> 3 months (or equivalent) of osteoporosis treatment currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
study examining exenatide long-acting release in subjects with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: exenatide lar is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. this study will assess the safety, tolerability, and pharmacokinetics of exenatide lar administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * has type 2 diabetes treated with either: \*a stable regimen of metformin for a minimum of 3 months, and/or \*diet modification and exercise for a minimum of 3 months. * has hba1c of 7.1% to 11.0%, inclusive. * has a body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive. exclusion criteria: * received any investigational drug within 3 months prior to screening. * is currently treated with any of the following excluded medications: \*thiazolidinediones within 3 months of screening; \* sulfonylureas within 3 months of screening; \* insulin within 1 year of screening. * participated previously in an exenatide clinical study.

Keywords: diabetes exenatide long acting release amylin lilly
effect of darbepoetin in contrast-induced nephropathy

Conditions: Acute Kidney Injury

Summary: the purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney disease.

use of radiocontrast agent is inevitable in computed tomography or angiography. however, contrast agent can aggravate kidney function. contrast-induced nephropathy (cin) refers to the clinical situation where decreased kidney function after use of contrast. cin is the 3rd most common cause of acute kidney injury in the hospitals. there are a lot of reports that death rate is increased in patients with cin. erythropoietin is an agent that treat anemia. it also has been reported to have a tissue-protective effect in the animal experiments. in this study, we hypothesized that erythropoietin can reduce the incidence of cin in patients with chronic kidney disease undergoing coronary angiography.

Eligibility criteria:
inclusion criteria: * age over 18 yr * estimated glomerular filtration rate (gfr) \< 60 ml/min/1.73m2 exclusion criteria: * chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal replacement therapy) * pregnancy or lactation * use of contrast agent within 1 week * emergent cag or pci * not recovered from aki(acute kidney injury) * use of nephrotoxic drugs within 48 hr * cardiogenic shock (sbp(systolic blood pressure) \< 90 mmhg) or pulmonary edema * uncontrolled hypertension (sbp ≥ 200 mmhg or dbp(diastolic blood pressure) ≥ 130 mmhg) * history of hypersensitivity to contrast agent * known allergy or hypersensitivity to epo(erythropoietin) * use of epo within 1 month * anemia (hemoglobin \< 9 g/dl) * ventilatory care

Keywords: darbepoetin, chronic kidney disease, coronary angiography